Dante Labs whole-genome test ends years of mystery infections for Dubai boy

A Dante Labs whole-genome test helped identify the cause of a young boy’s repeated infections in Dubai: chronic granulomatous disease linked to an NCF1 variant. The same report also flagged voriconazole as unlikely to work, steering his care toward a different antifungal plan and a bone marrow transplant.

Why it matters: - The result gave Alexander’s care team a clear diagnosis after years of infections, abnormal blood tests and no unifying explanation. - The same genome report also changed treatment planning by identifying a likely ineffective antifungal before it was used. - Chronic granulomatous disease is rare, but delayed diagnosis can lead to serious bacterial and fungal infections that damage organs over time.

What happened: - Dante Omics AI said a Dante Labs Whole Genome test ordered through DanteLabs.com identified a homozygous pathogenic variant in the NCF1 gene in Alexander, a young boy treated in Dubai. - The finding was consistent with chronic granulomatous disease type 1, a rare inherited immune disorder. - Alexander’s pediatrician, described as the Head for Paediatric Genomics at a top hospital in Dubai, ordered the test after earlier workups failed to explain his symptoms. - The report also identified Alexander as a rapid metabolizer of voriconazole.

The details: - Alexander’s early history included recurrent skin infections in infancy, dysmorphic features, elevated IgE, IgG and IgM, and chronic anemia that did not respond to iron supplements. - Hyper IgE syndrome was considered, but normal eosinophil counts and the absence of eczema made that diagnosis less likely. - Alexander’s DNA was collected with a non-invasive kit designed to be suitable for newborns. - The Dante Labs Whole Genome test sequenced the full genome at clinical-grade 30X coverage. - The analysis found a homozygous nonsense variant in exon 7 of NCF1. - The variant was classified as pathogenic in ClinVar and linked to chronic granulomatous disease type 1. - NCF1 encodes one component of the NADPH oxidase complex, which phagocytes use to generate the oxidative burst needed to kill microbes. - Flow cytometry and oxidative burst testing confirmed the abnormal oxidative burst associated with the disease. - Further testing found chronic fungal abscesses in Alexander’s spleen. - The pharmacogenomic report indicated voriconazole would likely remain ineffective even at high doses because Alexander metabolizes it rapidly. - His team used itraconazole for antifungal and antibacterial prophylaxis instead. - The reports were powered by the Dante Omics Versa Platform.

Between the lines: - The case shows why whole-genome sequencing can be more useful than narrower gene panels when symptoms do not fit one clear diagnosis. - It also shows how pharmacogenomic data can affect care before treatment failure happens, not just after. - Early genome screening may be especially valuable in recessive conditions, including families and communities where relatives are more likely to marry. - Chronic granulomatous disease is estimated to affect about 1 in 200,000 to 250,000 people worldwide. - Children with the disease often face repeated infections of the lungs, skin, liver and lymph nodes, plus inflammatory complications such as digestive tract granulomas. - Dante Omics AI CEO Andrea Riposati said, “We provide powerful tools to doctors for their patients. We work together to save lives.”

What’s next: - Alexander underwent a bone marrow transplant at a specialized center. - Bone marrow transplant is the established therapy that replaces the blood-forming stem cells responsible for the defective immune response in chronic granulomatous disease. - The transplant gives Alexander a chance at a complete recovery and a healthier childhood. - His case may be used as a model for earlier genomic screening in children with unexplained, treatment-resistant infections.

The bottom line: - One whole-genome test delivered both a diagnosis and a treatment signal, turning years of uncertainty into a clearer path forward for Alexander’s care.